NCT07446465 2026-03-03
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Phase 4 Not yet recruiting
Clinical Trials
40 trialsNCT07136077 2026-02-27
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06356597 2026-02-24
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting
NCT05954429 2026-01-22
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
Fudan University
Phase 2 Recruiting
NCT07353268 2026-01-20
Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07042685 2026-01-16
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT06856837 2025-12-12
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07229872 2025-11-17
A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment
Harbin Medical University
Phase 2 Not yet recruiting
NCT07150403 2025-09-08
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Not yet recruiting
NCT06441565 2025-07-30
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Sun Yat-sen University
Phase 2/3 Recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06985316 2025-05-22
An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
Tongji Hospital
Phase NA Not yet recruiting
NCT06980532 2025-05-20
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Tongji Hospital
Phase 1/2 Recruiting
NCT06714903 2024-12-04
Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer
The First Hospital of Jilin University
Recruiting
NCT06551207 2024-08-13
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Tongji Hospital
Phase NA Recruiting
NCT06543836 2024-08-09
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05690035 2024-07-09
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Sun Yat-sen University
Phase 2 Withdrawn
NCT06470178 2024-06-24
A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents
Wuhan University
Not yet recruiting
NCT06148402 2024-05-13
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT05661357 2024-04-17
HCCSC-C03
Zhongnan Hospital
Phase 4 Active not recruiting
NCT06234007 2024-03-18
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT05435313 2024-01-17
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Phase 2 Unknown
NCT05522738 2024-01-08
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT06195670 2024-01-08
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
Zhejiang Cancer Hospital
Phase 1/2 Not yet recruiting
NCT06168786 2023-12-21
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06118762 2023-11-07
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
The First Affiliated Hospital of Nanchang University
Phase 4 Recruiting
NCT06031376 2023-09-11
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Completed
NCT06018714 2023-08-31
Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study
Sun Yat-sen University
Phase 2 Recruiting
NCT05025631 2023-04-28
DOFEMCRC
Sichuan University
Phase 2 Completed
NCT05747716 2023-02-28
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05634590 2022-12-02
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT05511051 2022-08-22
A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05004831 2022-08-18
Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
Sun Yat-sen University
Phase 2 Unknown
NCT04733963 2022-07-26
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04866862 2022-07-25
Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05451719 2022-07-12
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT05447715 2022-07-07
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT05292417 2022-03-31
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown
NCT04948034 2021-08-27
The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
Fudan University
Phase 2 Unknown
NCT04431791 2020-06-16
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
Peking University
Unknown